News

Public · Published

Conavi Medical Presents Data Demonstrating Feasibility of Saline-Based Hybrid IVUS–OCT Imaging with OCTIV™ at TCT 2026

Conavi Medical presented animal-model data at TCT 2026 showing its OCTIV hybrid IVUS–OCT imaging system can use saline instead of iodinated contrast during image acquisition. The FDA-cleared system is now in commercial clinical use, with its first U.S. placement completed and patient cases ongoing.

Published:

Updated:

What happened

Conavi Medical presented animal-model data at TCT 2026 showing its OCTIV hybrid IVUS–OCT imaging system can use saline instead of iodinated contrast during image acquisition. The FDA-cleared system is now in commercial clinical use, with its first U.S. placement completed and patient cases ongoing.

Confirmed

Global impact / market context

If saline can replace iodinated contrast, patients may avoid contrast-related kidney risks, widening who can be imaged. For Conavi, that supports adoption of its OCTIV system and could increase procedure volume, device revenue and repeat use, though the evidence so far comes only from animals.

Analyst inference

Investors are weighing early feasibility data against commercial traction, since the first U.S. placement and ongoing patient cases show real revenue potential. The key test is whether human studies confirm saline-based imaging works, which would position OCTIV against contrast-dependent intravascular imaging competitors.

Analyst inference

What to watch

  1. The study used a porcine animal model before OCTIV's use in patients, so results are preliminary and not proven in humans. Confirmed
  2. Watch for human clinical studies testing saline-based hybrid IVUS–OCT imaging, which would be needed to confirm the contrast-free approach works in patients. Proposed
  3. Track U.S. hospital adoption and patient case growth, since expanding placements and procedure volume would indicate commercial demand for the FDA-cleared OCTIV system. Analyst inference

Evidence